REG - GSK PLC - GSK to acquire T cell-engager for multiple myeloma
RNS Number: 6877U GSK PLC 15 September 2026 Issued: 15 September 2026, London UKGSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen BiosciencesGSK plc (LSE/NYSE: GSK) today announced it has entered an agreement to acquire a potential best-in-clas…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.